Research on the Effect of Tongxinluo on Macrophage Foam Cell Formation

Authors

  • Mengshuang Ding
  • Zihao Wang
  • Hua Li
  • Yuxin Zhang

DOI:

https://doi.org/10.54691/kwxdh543

Keywords:

Tongxinluo; Macrophage foam cell formation; Inflammation; ox-LDL.

Abstract

Objective: To investigate the effect of Tongxinluo (TXL) on the foam cell formation of macrophages (RAW264.7).  Methods: In vitro experiment: Cultured RAW264.7 mouse monocyte macrophages were divided into four groups: control group, model group, TXL treatment group, and DMSO group. A foam cell model was induced by incubating the macrophages with 50 μg/mL oxidized low-density lipoprotein (ox-LDL). The TXL treatment group was intervened with 100 μg/mL Tongxinluo. Lipid deposition within macrophages was observed using Oil Red O staining; cell proliferation activity was detected via a CCK-8 assay kit; and the levels of inflammatory factors (TNF-α, IL-1β, and IL-6) in the cell culture supernatant were measured by ELISA. Results: Compared with the control group, the model group exhibited a significant downregulation of macrophage proliferation activity, markedly increased lipid deposition, and a substantial increase in the release of inflammatory factors TNF-α, IL-1β, and IL-6 into the supernatant. In contrast to the model group, the TXL treatment group showed a significant upregulation of proliferation activity, markedly reduced lipid deposition, and a significant downregulation in the release of TNF-α, IL-1β, and IL-6. No significant changes in these indicators were observed in the solvent control (DMSO) group compared to the model group. Conclusion: Tongxinluo can significantly inhibit foam cell formation in macrophages and attenuate macrophage-mediated inflammatory injury.

Downloads

Download data is not yet available.

References

[1] Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci. 2020;21(20):7609.

[2] Yu HX. Correlation between homocysteine level and carotid atherosclerosis in elderly patients. Mod J Integr Tradit Chin West Med. 2020;29(04):391-394.

[3] Fang TF, Jiang M, Hu YW. Research progress on tissue-resident macrophages in atherosclerotic plaques. Chin J Cardiol. 2024;29(03):283-288.

[4] Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018;8(3):80.

[5] Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104:114-124.

[6] Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786.

[7] Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(6):705-716.

[8] Chen WQ, Zhong L, Zhang L, et al. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. J Ethnopharmacol. 2009;124(1):103-110.

[9] Liu W, Li XX, Lin Q, et al. Systematic evaluation of Tongxinluo capsule combined with atorvastatin in the treatment of carotid atherosclerosis. Drug Eval Res. 2024;47(02):389-400.

[10] Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394-405.

[11] Bonati LH, Jansen O, de Borst GJ, et al. Management of atherosclerotic extracranial carotid artery stenosis. Lancet Neurol. 2022;21(3):273-283.

[12] Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533.

[13] Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-1374.

[14] Bai B, Yang Y, Ji S, et al. MicroRNA‐302c‐3p inhibits endothelial cell pyroptosis via directly targeting NOD‐, LRR‐and pyrin domain‐containing protein 3 in atherosclerosis. J Cell Mol Med. 2021; 25(9): 4373-4386.

[15] Liu Q, Zhang D, Hu D, et al. The role of mitochondria in NLRP3 inflammasome activation. Mol Immunol. 2018;103:115-124.

[16] Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41(1):301-316.

[17] Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131.

[18] Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709-721.

[19] Wu YL. Discussion on Collateral Disease Theory [M]. Beijing: China Science and Technology Press; 2010:670.

[20] Wu YL. Collaterology [M]. Beijing: China Press of Traditional Chinese Medicine; 2006:179-180.

[21] Li HR, Zhang X, Chang LP, et al. Research progress on anti-atherosclerosis effect of Tongxinluo Capsule. Chin Tradit Pat Med. 2016;38(2):386-391.

Downloads

Published

16-10-2025

Issue

Section

Articles

How to Cite

Ding, M., Wang, Z., Li, H., & Zhang, Y. (2025). Research on the Effect of Tongxinluo on Macrophage Foam Cell Formation. Frontiers in Humanities and Social Sciences, 5(10), 239-245. https://doi.org/10.54691/kwxdh543